MOTS-c: Safety, Legal Status, and Human Evidence

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. It was described in 2015 as a signaling peptide made from mitochondrial rather than nuclear DNA. Its name stands for mitochondrial open reading frame of the 12S rRNA-c.

It is sometimes marketed as an exercise mimetic. That framing comes from animal studies only.

In the foundational mouse and cell work, MOTS-c acted mainly on skeletal muscle. It inhibited the folate cycle and purine synthesis, which led to activation of AMPK, an energy-sensing enzyme. In mice it prevented age-related and diet-induced insulin resistance and diet-induced obesity.

Later work in cells and obese mice linked MOTS-c to lower myostatin, a signal that limits muscle mass, through a chain of muscle signaling pathways. These mechanisms are preclinical. They have not been confirmed as effects of MOTS-c given to people.

Human data come from measurements of the body's own MOTS-c. One study reported that exercise raises MOTS-c in human skeletal muscle and in the blood. Another found that people with higher blood MOTS-c tended to have lower myostatin. Neither study gave MOTS-c to people, and a correlation does not show cause.

In the Nature Communications study, mice given MOTS-c, including old mice, showed better physical performance and healthspan measures. Whether any of this applies to humans has not been tested in a published controlled trial among the sources reviewed here.

The three main studies share authors from the same University of Southern California group. In the two 2021 studies, authors disclosed that they were consultants and shareholders of CohBar, Inc. Independent replication matters here.

Human safety of MOTS-c given as a product is unknown. No reviewed source reports a controlled human safety study. Online reports of side effects cannot establish whether MOTS-c caused them, how often they occur, or what long-term risks exist.

Products sold online as research peptides are not reviewed by a regulator for identity, purity or sterility. Questions about cancer risk, heart effects or use in pregnancy cannot be answered from the available evidence.

MOTS-c is not approved by the FDA or Health Canada. It does not appear in Drugs@FDA or in Health Canada's Drug Product Database. FDA lists it among bulk substances nominated for compounding but withdrawn after being placed in category 2. FDA cites a possible significant risk of immune reactions, complex peptide impurities, and no human exposure data.

The 2026 WADA Prohibited List names MOTS-c under S4.4.1, metabolic modulators, as an activator of the AMPK enzyme. Substances in this class are prohibited at all times, in and out of competition.